Advancing Terbium-Based Radiopharmaceuticals Manufacturing to Unlock More Versatile Theranostic & Therapeutic Strategies

• Exploring the unique theranostic potential of the terbium isotope family including alpha-, beta- and imaging-emitting variants capable of supporting matched diagnostic and therapeutic applications
• Understanding how terbium’s emission characteristics, tissue penetration and decay profile may enable more flexible treatment strategies across different tumour settings
• Addressing the manufacturing, purification and large-scale supply challenges that must be solved before terbium-based therapies can achieve broader clinical adoption

Session reserved for Novartis